• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

述评:生理药代动力学肠道模型中对肠道和全身利用率的流动效应的理论预测:传统模型、分隔流动模型和 QGut 模型。

Commentary: theoretical predictions of flow effects on intestinal and systemic availability in physiologically based pharmacokinetic intestine models: the traditional model, segregated flow model, and QGut model.

出版信息

Drug Metab Dispos. 2012 Oct;40(10):1869-77. doi: 10.1124/dmd.112.045872. Epub 2012 Jun 27.

DOI:10.1124/dmd.112.045872
PMID:22745334
Abstract

Physiologically based pharmacokinetic (PBPK) models for the intestine, comprising of different flow rates perfusing the enterocyte region, were revisited for appraisal of flow affects on the intestinal availability (F(I)) and, in turn, the systemic availability (F(sys)) and intestinal versus liver contribution to the first-pass effect during oral drug absorption. The traditional model (TM), segregated flow model (SFM), and effective flow (Q(Gut)) model stipulate that 1.0, ∼0.05 to 0.3, and ≤0.484× of the total intestinal flow, respectively, reach the enterocyte region that houses metabolically active and transporter-enriched enterocytes. The fractional flow rate to the enterocyte region (f(Q)), when examined under varying experimental conditions, was found to range from 0.024 to 0.2 for the SFM and 0.065 to 0.43 for the Q(Gut) model. Appraisal of these flow intestinal models, when used in combination with whole-body PBPK models, showed the ranking as SFM < Q(Gut) model < TM in the description of F(I), and the same ranking existed for the contribution of the intestine to first-pass removal. However, the ranking for the predicted contribution of hepatic metabolism, when present, to first-pass removal was the opposite: SFM > Q(Gut) model > TM. The findings suggest that the f(Q) value strongly influences the rate of intestinal metabolism (F(I) and F(sys)) and indirectly affects the rate of liver metabolism due to substrate sparing effect. Thus, the f(Q) value in the intestinal flow models pose serious implications on the interpretation of data on the first-pass effect and oral absorption of drugs.

摘要

肠的生理基础药代动力学(PBPK)模型,包括不同的流量灌注肠细胞区,被重新评估了流量对肠内可用性(F(I))的影响,进而影响了系统可用性(F(sys))和肠与肝对口服药物吸收过程中的首过效应的贡献。传统模型(TM)、分离流模型(SFM)和有效流(Q(肠道))模型分别规定,1.0、约 0.05 至 0.3、≤0.484×的总肠道流量分别到达含有代谢活跃和富含转运蛋白的肠细胞的肠细胞区。当在不同的实验条件下检查到肠细胞区的分数流量(f(Q))时,发现 SFM 的范围为 0.024 至 0.2,而 Q(肠道)模型的范围为 0.065 至 0.43。当与全身 PBPK 模型结合使用时,对这些肠道流量模型的评估表明,在描述 F(I)方面,SFM< Q(肠道)模型< TM 的排名,而在肠对首过消除的贡献方面也存在相同的排名。然而,当存在时,预测肝代谢对首过消除的贡献的排名则相反:SFM> Q(肠道)模型> TM。研究结果表明,f(Q)值强烈影响肠道代谢率(F(I)和 F(sys)),并由于底物节约效应间接影响肝脏代谢率。因此,肠道流量模型中的 f(Q)值对首过效应和药物口服吸收数据的解释有严重影响。

相似文献

1
Commentary: theoretical predictions of flow effects on intestinal and systemic availability in physiologically based pharmacokinetic intestine models: the traditional model, segregated flow model, and QGut model.述评:生理药代动力学肠道模型中对肠道和全身利用率的流动效应的理论预测:传统模型、分隔流动模型和 QGut 模型。
Drug Metab Dispos. 2012 Oct;40(10):1869-77. doi: 10.1124/dmd.112.045872. Epub 2012 Jun 27.
2
Theoretical consideration of the properties of intestinal flow models on route-dependent drug removal: Segregated Flow (SFM) vs. Traditional (TM).肠流模型对随路径清除药物的特性的理论思考:分隔流(SFM)与传统(TM)。
Biopharm Drug Dispos. 2019 May;40(5-6):195-213. doi: 10.1002/bdd.2184.
3
Unequivocal evidence supporting the segregated flow intestinal model that discriminates intestine versus liver first-pass removal with PBPK modeling.有明确证据支持通过生理药代动力学(PBPK)模型区分肠道与肝脏首过消除的分流肠道模型。
Biopharm Drug Dispos. 2017 Apr;38(3):231-250. doi: 10.1002/bdd.2056. Epub 2017 Mar 28.
4
PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism.药物吸收和连续代谢中肠道和肝脏酶及转运体的 PBPK 建模。
Curr Drug Metab. 2010 Nov;11(9):743-61. doi: 10.2174/138920010794328931.
5
Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.代谢与转运在决定口服药物吸收和肠道壁代谢中的相互作用:应用“先进的溶解、吸收、代谢(ADAM)”模型进行的模拟评估。
Curr Drug Metab. 2010 Nov;11(9):716-29. doi: 10.2174/138920010794328913.
6
Metabolite Kinetics: The Segregated Flow Model for Intestinal and Whole Body Physiologically Based Pharmacokinetic Modeling to Describe Intestinal and Hepatic Glucuronidation of Morphine in Rats In Vivo.代谢物动力学:用于肠道和全身基于生理的药代动力学建模的分离流模型,以描述大鼠体内吗啡的肠道和肝脏葡萄糖醛酸化。
Drug Metab Dispos. 2016 Jul;44(7):1123-38. doi: 10.1124/dmd.116.069542. Epub 2016 Apr 20.
7
Physiologically based pharmacokinetic modeling revealed minimal codeine intestinal metabolism in first-pass removal in rats.基于生理的药代动力学模型显示,大鼠首过消除过程中可待因的肠道代谢极少。
Biopharm Drug Dispos. 2017 Jan;38(1):50-74. doi: 10.1002/bdd.2051.
8
A new physiologically based, segregated-flow model to explain route-dependent intestinal metabolism.一种基于生理学的新型分流模型,用于解释肠道代谢的途径依赖性。
Drug Metab Dispos. 2000 Feb;28(2):224-35.
9
Why we need proper PBPK models to examine intestine and liver oral drug absorption.为什么我们需要合适的 PBPK 模型来研究肠道和肝脏的口服药物吸收。
Curr Drug Metab. 2013 Jan;14(1):57-79.
10
Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption.肠道节段性转运体和代谢酶对肠道药物吸收的影响
Drug Metab Dispos. 2003 Apr;31(4):373-83. doi: 10.1124/dmd.31.4.373.

引用本文的文献

1
The Segregated Intestinal Flow Model (SFM) for Drug Absorption and Drug Metabolism: Implications on Intestinal and Liver Metabolism and Drug-Drug Interactions.用于药物吸收和药物代谢的分离肠内流模型(SFM):对肠和肝脏代谢以及药物-药物相互作用的影响
Pharmaceutics. 2020 Apr 1;12(4):312. doi: 10.3390/pharmaceutics12040312.
2
A comparative evaluation of models to predict human intestinal metabolism from nonclinical data.从非临床数据预测人体肠道代谢的模型的比较评估。
Biopharm Drug Dispos. 2017 Apr;38(3):163-186. doi: 10.1002/bdd.2068.
3
Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models.
预测人体肠壁中的药物提取:使用临床前模型评估药物代谢酶和转运蛋白的作用。
Clin Pharmacokinet. 2016 Jun;55(6):673-96. doi: 10.1007/s40262-015-0351-6.
4
Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug-Drug Interactions.马昔腾坦的生理药代动力学建模:药物相互作用预测
Clin Pharmacokinet. 2016 Mar;55(3):369-80. doi: 10.1007/s40262-015-0322-y.
5
ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans.国际理论化学与应用化学联合会关于转运体动力学参数估算以及人类转运体介导的 PK 和 DDI 转化模型的建议。
Clin Pharmacol Ther. 2013 Jul;94(1):64-79. doi: 10.1038/clpt.2013.45. Epub 2013 Feb 25.